Literature DB >> 23418348

cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon.

Raphaela Schwappacher1, Hema Rangaswami, Jacqueline Su-Yuo, Aaron Hassad, Ryan Spitler, Darren E Casteel.   

Abstract

The two isoforms of type I cGMP-dependent protein kinase (PKGIα and PKGIβ) differ in their first ∼100 amino acids, giving each isoform unique dimerization and autoinhibitory domains. The dimerization domains form coiled-coil structures and serve as platforms for isoform-specific protein-protein interactions. Using the PKGIβ dimerization domain as an affinity probe in a proteomic screen, we identified the actin/myosin-associated protein caldesmon (CaD) as a PKGIβ-specific binding protein. PKGIβ phosphorylated human CaD on serine 12 in vitro and in intact cells. Phosphorylation on serine 12 or mutation of serine 12 to glutamic acid (S12E) reduced the interaction between CaD and myosin IIA. Because CaD inhibits myosin ATPase activity and regulates cell motility, we examined the effects of PKGIβ and CaD on cell migration and invasion. Inhibition of the NO/cGMP/PKG pathway reduced migration and invasion of human breast cancer cells, whereas PKG activation enhanced their motility and invasion. siRNA-mediated knockdown of endogenous CaD had pro-migratory and pro-invasive effects in human breast cancer cells. Reconstituting cells with wild-type CaD slowed migration and invasion; however, CaD containing a phospho-mimetic S12E mutation failed to reverse the pro-migratory and pro-invasive activity of CaD depletion. Our data suggest that PKGIβ enhances breast cancer cell motility and invasive capacity, at least in part, by phosphorylating CaD. These findings identify a pro-migratory and pro-invasive function for PKGIβ in human breast cancer cells, suggesting that PKGIβ is a potential target for breast cancer treatment.

Entities:  

Keywords:  Caldesmon; Human breast cancer cells; Invasion; Migration; cGMP-dependent protein kinase

Mesh:

Substances:

Year:  2013        PMID: 23418348      PMCID: PMC3647439          DOI: 10.1242/jcs.118190

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  68 in total

1.  Elastin-derived peptide induces monocyte chemotaxis by increasing intracellular cyclic GMP level and activating cyclic GMP dependent protein kinase.

Authors:  Y Uemura; K Okamoto
Journal:  Biochem Mol Biol Int       Date:  1997-01

2.  TFII-I enhances activation of the c-fos promoter through interactions with upstream elements.

Authors:  D W Kim; V Cheriyath; A L Roy; B H Cochran
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

3.  The involvement of protein kinase G in stimulation of neutrophil migration by endothelins.

Authors:  J G Elferink; B M De Koster
Journal:  Eur J Pharmacol       Date:  1998-06-05       Impact factor: 4.432

4.  Different molecular mechanisms for Rho family GTPase-dependent, Ca2+-independent contraction of smooth muscle.

Authors:  J E Van Eyk; D K Arrell; D B Foster; J D Strauss; T Y Heinonen; E Furmaniak-Kazmierczak; G P Côté; A S Mak
Journal:  J Biol Chem       Date:  1998-09-04       Impact factor: 5.157

5.  Both N-terminal myosin-binding and C-terminal actin-binding sites on smooth muscle caldesmon are required for caldesmon-mediated inhibition of actin filament velocity.

Authors:  Z Wang; H Jiang; Z Q Yang; S Chacko
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Involvement of intracellular cyclic GMP and cyclic GMP-dependent protein kinase in alpha-elastin-induced macrophage chemotaxis.

Authors:  S Kamisato; Y Uemura; N Takami; K Okamoto
Journal:  J Biochem       Date:  1997-05       Impact factor: 3.387

7.  Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology.

Authors:  C Brown; X Pan; A Hassid
Journal:  Circ Res       Date:  1999-04-02       Impact factor: 17.367

8.  Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling.

Authors:  Y M Kim; H T Chung; S S Kim; J A Han; Y M Yoo; K M Kim; G H Lee; H Y Yun; A Green; J Li; R L Simmons; T R Billiar
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

9.  Differential expression of Hela-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells.

Authors:  Ping-Pin Zheng; M van der Weiden; Johan M Kros
Journal:  J Pathol       Date:  2005-02       Impact factor: 7.996

10.  The role of caldesmon in the regulation of endothelial cytoskeleton and migration.

Authors:  Tamara Mirzapoiazova; Irina A Kolosova; Lew Romer; Joe G N Garcia; Alexander D Verin
Journal:  J Cell Physiol       Date:  2005-06       Impact factor: 6.384

View more
  17 in total

1.  The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression.

Authors:  Christopher S Rabender; Asim Alam; Gobalakrishnan Sundaresan; Robert J Cardnell; Vasily A Yakovlev; Nitai D Mukhopadhyay; Paul Graves; Jamal Zweit; Ross B Mikkelsen
Journal:  Mol Cancer Res       Date:  2015-02-27       Impact factor: 5.852

2.  The activity of cGMP-dependent protein kinase Iα is not directly regulated by oxidation-induced disulfide formation at cysteine 43.

Authors:  Hema Kalyanaraman; Shunhui Zhuang; Renate B Pilz; Darren E Casteel
Journal:  J Biol Chem       Date:  2017-03-30       Impact factor: 5.157

3.  Crystal structure of the cGMP-dependent protein kinase II leucine zipper and Rab11b protein complex reveals molecular details of G-kinase-specific interactions.

Authors:  Albert S Reger; Matthew P Yang; Shizuyo Koide-Yoshida; Elaine Guo; Shrenik Mehta; Keizo Yuasa; Alan Liu; Darren E Casteel; Choel Kim
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

4.  A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP.

Authors:  Matthew H Chan; Sahar Aminzai; Tingfei Hu; Amatya Taran; Sheng Li; Choel Kim; Renate B Pilz; Darren E Casteel
Journal:  J Biol Chem       Date:  2020-06-05       Impact factor: 5.157

5.  Inhibition of soluble guanylyl cyclase by small molecules targeting the catalytic domain.

Authors:  Jagamya Vijayaraghavan; Kristopher Kramp; Michael E Harris; Focco van den Akker
Journal:  FEBS Lett       Date:  2016-10-04       Impact factor: 4.124

6.  Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon.

Authors:  Sascha Dierks; Sandra von Hardenberg; Thomas Schmidt; Felix Bremmer; Peter Burfeind; Silke Kaulfuß
Journal:  Oncotarget       Date:  2015-05-30

7.  Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.

Authors:  David Britton; Yoh Zen; Alberto Quaglia; Stefan Selzer; Vikram Mitra; Christopher Löβner; Stephan Jung; Gitte Böhm; Peter Schmid; Petra Prefot; Claudia Hoehle; Sasa Koncarevic; Julia Gee; Robert Nicholson; Malcolm Ward; Leandro Castellano; Justin Stebbing; Hans Dieter Zucht; Debashis Sarker; Nigel Heaton; Ian Pike
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

8.  Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.

Authors:  Myung-Shin Lee; Jisu Lee; Joo Heon Kim; Won Tae Kim; Wun-Jae Kim; Hanjong Ahn; Jinsung Park
Journal:  Oncotarget       Date:  2015-11-24

9.  Cyclin D3 predicts disease-free survival in breast cancer.

Authors:  Yayun Chi; Sheng Huang; Mengying Liu; Liang Guo; Xuxia Shen; Jiong Wu
Journal:  Cancer Cell Int       Date:  2015-09-26       Impact factor: 5.722

10.  Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

Authors:  Tommaso De Marchi; Anne M Timmermans; Marcel Smid; Maxime P Look; Christoph Stingl; Mark Opdam; Sabine C Linn; Fred C G J Sweep; Paul N Span; Mike Kliffen; Carolien H M van Deurzen; Theo M Luider; John A Foekens; John W Martens; Arzu Umar
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.